<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03915626</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00076010</org_study_id>
    <nct_id>NCT03915626</nct_id>
  </id_info>
  <brief_title>Effect of Heat on Rivastigmine TDS Products</brief_title>
  <official_title>Determination of Serum Rivastigmine Levels After Using Rivastigmine Transdermal Delivery Systems With and Without Standardized Heat Application in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is designed to measure the amount of medicine in blood over time after
      the patch is placed on the skin with and without external heat application.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rivastigmine concentration of collected serum samples</measure>
    <time_frame>0-12 hours for each subject for each of the four study arms (10-12 weeks)</time_frame>
    <description>rivastigmine in serum</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>RLD patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RLD patch with heat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic patch with heat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine (RLD) transdermal patch</intervention_name>
    <description>brand name patch</description>
    <arm_group_label>RLD patch</arm_group_label>
    <arm_group_label>RLD patch with heat</arm_group_label>
    <other_name>brand name patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine (generic) transdermal patch</intervention_name>
    <description>generic patch</description>
    <arm_group_label>generic patch</arm_group_label>
    <arm_group_label>generic patch with heat</arm_group_label>
    <other_name>generic patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or non-pregnant, non-lactating women who are of any ethnic background between the
             age of 18 to 45 years old

          2. Subjects must be non-smokers/tobacco users (must have refrained from the use of
             nicotine-containing substances, including tobacco products (e.g., cigarettes, cigars,
             chewing tobacco, snuff, gum, patches or electronic cigarettes) over the previous 2
             months and are not currently using tobacco products

          3. Provide written informed consent before initiation of any of the study procedures

          4. Agree not to participate in another clinical trial/study or to participate in an
             investigational drug study for at least one month after the last study session

          5. Able to adhere to the study restrictions and protocol schedule

          6. Able to participate in all study sessions

          7. Subjects deemed to be healthy as judged by the Medically Accountable Investigator
             (MAI) and determined by medical history, physical examination and medication history

          8. Negative urine drug screening test (cannabinoids, amphetamines, barbiturates,
             benzodiazepine, cocaine, methadone, opiates, PCP)

          9. Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb),
             platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN),
             creatinine, alanine transaminase (ALT) and aspartate aminotransferase (AST)

         10. Have normal screening laboratories for urine protein and urine glucose

         11. Female subjects must be of non-childbearing potential (as defined as surgically
             sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more
             than 1 year), or if of childbearing potential must be non-pregnant at the time of
             enrollment and on the morning of each procedure day, and must agree to use reliable
             hormonal or barrier birth control such as implants, injectables, combined oral
             contraceptives, some intrauterine devices (IUDs), sexual abstinence or a vasectomized
             partner

         12. Agree not to donate blood to a blood bank throughout participation in the study and
             for at least three months after last procedure day

         13. Have a normal ECG; must not have the following to be acceptable: pathologic Q wave
             abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right
             bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats
             per minute)

         14. Have normal vital signs:

               -  Temperature 35-37.9°C (95-100.3°F)

               -  Systolic blood pressure 90-140 mmHg

               -  Diastolic blood pressure 60-90 mmHg

               -  Heart rate 55-100 beats per minute

               -  Respiration rate 12-20 breaths per minute

        Exclusion Criteria:

          1. Women who are pregnant, lactating, breast feeding or have a positive serum pregnancy
             test at enrollment or positive urine pregnancy test on the morning of any study
             session

          2. Smokers/tobacco users (current use or use over the previous 2 months of
             nicotine-containing substances, including tobacco products (e.g., cigarettes, cigars,
             chewing tobacco, snuff, gum, patch or electronic cigarettes)

          3. Participation in any ongoing investigational drug trial/study or clinical drug
             trial/study

          4. History of lung, heart, respiratory or blood disease

          5. Active positive Hepatitis B, C and/or HIV serologies

          6. Positive urine drug screening test

          7. Use of chronic prescription medications during the period 0 to 30 days; or
             over-the-counter medications (e.g. cholinomimetic drugs [used to treat diseases like
             acid reflux in children, glaucoma, dry mouth associated with Sjögren's Syndrome],
             anticholinergics [used to treat diseases like asthma, incontinence, gastrointestinal
             cramps, and muscular spasms], antihistamines, topical corticosteroids) and short term
             (&lt;30 days) prescription medications during the period 0-3 days before a study session
             vitamin, herbal supplements and birth control medications not included)

          8. Donation or loss of greater than one pint of blood within 60 days of entry to the
             study

          9. Any prior allergies to rivastigmine, other carbamate derivatives, other ingredients in
             the patch, to medical tape products or other skin patches

         10. Subject has problems with urinary retention, gastric retention or gastrointestinal
             obstruction

         11. Subject has continuous spasms, muscle contractions, motor restlessness, rigidity,
             slowness of movement, tremors or irregular jerky movements

         12. Subject has ulcers or gastrointestinal bleeding

         13. Subject has asthma or blocked airflow making it hard to breathe (COPD)

         14. Received an experimental agent (vaccine, drug, biologic, device, blood product or
             medication) within one month before enrollment in this study or expects to receive an
             experimental agent during the study

         15. Any condition that would, in the opinion of the Medically Accountable Investigator
             (MAI), place the subject at an unacceptable risk of injury or render the subject
             unable to meet the requirements of the protocol

         16. Consumption (food or drink) of alcohol within 24 h prior to dose administration

         17. History as either reported by the subject or evident to the investigator of infectious
             disease or skin infection or of chronic skin disease (e.g., psoriasis, atopic
             dermatitis)

         18. History of diabetes

         19. Hereditary skin disorders or any skin inflammatory conditions as reported by the
             subject or evident to the MAI

         20. History of significant dermatologic cancers (e.g., melanoma, squamous cell carcinoma)
             except basal cell carcinomas that were superficial and did not involve the
             investigative sites

         21. Subject has an obvious difference in skin color between arms or the presence of a skin
             condition, excessive hair at the application site (upper arms), sunburn, raised moles
             and scars, open sores at application site (upper arms), scar tissue, tattoo, or
             coloration that would interfere with placement of products, skin assessment, or
             reactions to rivastigmine

         22. BMI ≥30 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Audra L Stinchcomb, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore School of Pharmacy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danielle Fox</last_name>
    <phone>443-890-1020</phone>
    <email>danielle.fox@rx.umaryland.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Clinical Research Center (GCRC) at the University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Fox</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Audra Stinchcomb</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

